First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).

被引：0
|
作者：
Di Giacomo, Anna Maria
Santangelo, Federica
Amato, Giovanni
Simonetti, Elena
Graham, Jill
Lahn, Michael M. F.
Di Conza, Giusy
Hammett, Tracey
Zorrilla, Rebeca
Durini, Marco
Tan, Ziyang
Tadepally, Lakshmikanth
Brodin, Petter
Occhipinti, Mariaelena
Simonelli, Matteo
Carlo-Stella, Carmelo
Santoro, Armando
Spiliopoulou, Pavlina
Evans, T. R. Jeffry
Maio, Michele
机构：
[1] Univ Hosp Siena, Ctr Immuno Oncol, Siena, Italy
[2] Azienda Osped Univ Senese, UOC Immunoterapia Oncolog, Siena, Italy
[3] Univ Siena, Siena, Italy
[4] Beatson Canc Ctr, Glasgow, Lanark, Scotland
[5] iOnctura SA, Geneva, Switzerland
[6] Covance Clin & Peri Approval Serv LTD, Milan, Italy
[7] Karolinska Inst, Stockholm, Sweden
[8] Karolinska Inst, Dept Womens & Childrens Hlth, Sci Life Lab, Solna, Sweden
[9] Radiomics, Liege, Belgium
[10] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[11] Humanitas Univ, Milan, Italy
[12] IRCCS Humanitas Res Hosp, Milan, Italy
[13] IRCCS Humanitas Res Hosp, Rozzano, Italy
[14] Princess Margaret Canc Ctr Canada, Toronto, ON, Canada
[15] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3110
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
    Shunsuke Kondo
    Masaomi Tajimi
    Tomohiko Funai
    Koichi Inoue
    Hiroya Asou
    Vinay Kumar Ranka
    Volker Wacheck
    Toshihiko Doi
    Investigational New Drugs, 2020, 38 : 1836 - 1845
  • [42] First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma.
    Sosman, J. A.
    Adjei, A. A.
    LoRusso, P.
    Michael, S. A.
    Dy, G. K.
    Bowditch, A.
    Chmielowski, B.
    Lee, S.
    Walker, R. M.
    Faucette, S.
    Izmailova, E. S.
    Bozon, V.
    Ribas, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma
    Sharfman, W. H.
    Hodi, F. S.
    Lawrence, D. P.
    Flaherty, K. T.
    Amaravadi, R. K.
    Kim, K. B.
    Dummer, R.
    Gobbi, S.
    Puzanov, I.
    Sosman, J. A.
    Dohoney, K.
    Lam, L. P.
    Kakar, S.
    Tang, Z.
    Krieter, O.
    Atkins, M. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] First-in-human phase I dose-escalation study of the oral selective C-met inhibitor EMD 1204831 in patients with advanced solid tumors.
    Amin, Hesham M.
    Falchook, Gerald Steven
    Fu, Siqing
    Hong, David S.
    Tsimberidou, Apostolia Maria
    Naing, Aung
    Wheler, Jennifer J.
    Piha-Paul, Sarina Anne
    Janku, Filip
    Klevesath, Manfred B.
    Jego, Virginie
    Johne, Andreas
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] First-in-human study of the cancer peptide vaccine, TAS0313, in patients with advanced solid tumors: phase I dose finding part results
    Yamamoto, Noboru
    Sato, Jun
    Iwasa, Satoru
    Yonemori, Kan
    Koyama, Takafumi
    Tamura, Kenji
    Shimizu, Toshio
    Kondo, Syunsuke
    Kitano, Shigehisa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [46] First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations
    Wang, Xuan
    Luo, Zhiguo
    Chen, Jing
    Chen, Yu
    Ji, Dongmei
    Fan, Li
    Chen, Ling
    Zhao, Qian
    Hu, Pei
    Sun, Peng
    Jia, Zhongwei
    Guo, Jun
    Si, Lu
    BMC MEDICINE, 2023, 21 (01)
  • [47] First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations
    Xuan Wang
    Zhiguo Luo
    Jing Chen
    Yu Chen
    Dongmei Ji
    Li Fan
    Ling Chen
    Qian Zhao
    Pei Hu
    Peng Sun
    Zhongwei Jia
    Jun Guo
    Lu Si
    BMC Medicine, 21
  • [48] Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
    Rodon, Jordi
    Brana, Irene
    Siu, Lillian L.
    De Jonge, Maja J.
    Homji, Natasha
    Mills, David
    Di Tomaso, Emmanuelle
    Sarr, Celine
    Trandafir, Lucia
    Massacesi, Cristian
    Eskens, Ferry
    Bendell, Johanna C.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (04) : 670 - 681
  • [49] Phase I dose- escalation study of buparlisib ( BKM120), an oral pan- class I PI3K inhibitor, in Japanese patients with advanced solid tumors
    Ando, Yuichi
    Inada-Inoue, Megumi
    Mitsuma, Ayako
    Yoshino, Takayuki
    Ohtsu, Atsushi
    Suenaga, Naoko
    Sato, Masahiko
    Kakizume, Tomoyuki
    Robson, Matthew
    Quadt, Cornelia
    Doi, Toshihiko
    CANCER SCIENCE, 2014, 105 (03) : 347 - 353
  • [50] Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
    Jordi Rodon
    Irene Braña
    Lillian L Siu
    Maja J De Jonge
    Natasha Homji
    David Mills
    Emmanuelle Di Tomaso
    Celine Sarr
    Lucia Trandafir
    Cristian Massacesi
    Ferry Eskens
    Johanna C Bendell
    Investigational New Drugs, 2014, 32 : 670 - 681
12345